tiprankstipranks

Adma Biologics sees FY26 revenue $600M

Adma Biologics sees FY26 revenue $600M

Sees FY26 net income expected to exceed $230M; FY26 adjusted EBITDA expected to exceed $300M

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Questions or Comments about the article? Write to editor@tipranks.com